Risk of COVID-19 for Patients with Cancer: A Narrative Overview
Mohamed Amine Baba 1 2 * , Youssef Bouchriti 1 3, Abderrahmane Achbani 1 4, Ahmed Kharbach 1 5, Hasnaa Sine 6, Aziz Naciri 7
More Detail
1 High Institute of Nursing Professions and Technical Health, Agadir, Morocco2 National School of Applied Sciences, Ibn Zohr University, Agadir, Morocco3 Faculty of sciences Ibn Zohr, Agadir, Morocco4 Laboratory of Cell Biology and Molecular Genetics Department of Biology, Faculté of Sciences, Ibn Zohr University, Agadir, Morocco5 Laboratory of Biostatistics Clinical Research and Epidemiology (LBRCE) Faculty of Medicine and Pharmacy of Rabat, MOHAMED V University of Rabat, Morocco6 Medical Biology, Human and experimental pathology and Environment, Faculty of Medicine and Pharmacy of Rabat, MOHAMED V University of Rabat, Morocco7 High Institute of Nursing Professions and Technical Health, Laayoun, Morocco* Corresponding Author

Abstract

In March 2020, the WHO declared COVID-19 as a pandemic. At present, the curative vaccine has not yet been developed, older age and higher comorbidity levels are associated with more severe COVID-19 symptoms. Indeed, the cancer community currently faces many difficult questions.

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article Type: Review Article

EUROPEAN J MED ED TE, 2020, Volume 13, Issue 3, Article No: em2008

https://doi.org/10.30935/ejmets/8257

Publication date: 11 May 2020

Article Views: 2012

Article Downloads: 1049

Open Access References How to cite this article